Guardant Health (GH) announced the commencement of an underwritten public offering of $250M of shares of Guardant Health’s common stock. Guardant Health intends to use the net proceeds from the common stock offering for general corporate purposes, which may include, depending on market conditions, repurchasing a portion of Guardant Health’s 0% convertible senior notes due 2027. General corporate purposes may also include the acquisition of complementary products, technologies, intellectual property or businesses; however, Guardant Health currently does not have any agreements or commitments to complete any such transactions. Goldman Sachs & Co., Jefferies, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the common stock offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Cathie Wood Steps Up Bet on Bullish Stock (BLSH), Trims Stake in Palantir (PLTR) amid Strong Q3 Earnings
- Guardant Health price target raised to $100 from $70 at Stifel
- Guardant Health’s Q3 2025 Earnings: Strong Growth Amid Challenges
- This Is Why Guardant Health Stock (GH) Surged 30% Today
- Guardant Health rises 31.4%